Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Status:
COMPLETED
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized study to compare the efficacy of TP (Taxane plus Carboplatin) chemotherapy combined with dual-HER2 blockade (trastuzumab and pertuzumab) versus TP chemotherapy plus single-HER2 blockade (trastuzumab) in patients with HER2-positive breast cancer. The study aims to evaluate treatment response and the clinical value of serum tumor markers (CEA, CA125, and CA153) in assessing therapeutic efficacy.